English to Spanish Medical Medical: Pharmaceuticals Informed Consent

Treatment was generally well tolerated. There were slightly more reports of chills, flu-like syndrome, asthenia, nausea, and vomiting in the 1.0 mg and 4.0 mg/kg fontolizumab cohorts. Two serious adverse events rated as worsening of CD occurred under fontolizumab. By day 29, a more enhanced decrease in median Crohn’s disease endoscopic index of severity was observed in the 4.0 mg/kg fontolizumab cohort compared with placebo. Pharmacodynamic effects were observed by immunohistochemistry.